These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27105307)

  • 1. Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer.
    Plantinga TS; Tesselaar MH; Morreau H; Corssmit EP; Willemsen BK; Kusters B; van Engen-van Grunsven AC; Smit JW; Netea-Maier RT
    Autophagy; 2016 Jul; 12(7):1195-205. PubMed ID: 27105307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.
    Tesselaar MH; Crezee T; Schuurmans I; Gerrits D; Nagarajah J; Boerman OC; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
    J Nucl Med; 2018 May; 59(5):780-786. PubMed ID: 29242405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
    Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer.
    Crezee T; Tesselaar MH; Nagarajah J; Corver WE; Morreau J; Pritchard C; Kimura S; Kuiper JG; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
    Cell Oncol (Dordr); 2021 Jun; 44(3):611-625. PubMed ID: 33534128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
    Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
    Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
    Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
    Oh JM; Ahn BC
    Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na
    Singh TD; Lee JE; Son KH; Lee BR; Kim SK; Gulwani D; Sarangthem V; Jeon YH
    Cells; 2023 Feb; 12(3):. PubMed ID: 36766812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioactive iodine treatment for node negative papillary thyroid cancer with capsular invasion only: Results of a large retrospective study.
    Jeon YW; Ahn YE; Chung WS; Choi HJ; Suh YJ
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e167-73. PubMed ID: 24289279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
    Suh S; Kim YH; Goh TS; Jeong DC; Lee CS; Jang JY; Cha W; Han ME; Kim SJ; Kim IJ; Pak K
    Yonsei Med J; 2018 Aug; 59(6):746-753. PubMed ID: 29978611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
    Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
    Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin enhances the membrane trafficking of the sodium iodide symporter and augments radioiodine uptake in dedifferentiated thyroid cancer cells
    Zhang L; Xu S; Cheng X; Wu J; Wang X; Wu L; Yu H; Bao J
    Food Funct; 2021 Sep; 12(18):8260-8273. PubMed ID: 34323243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
    Cengic N; Baker CH; Schütz M; Göke B; Morris JC; Spitzweg C
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4457-64. PubMed ID: 15941870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma.
    van Houten P; Nagarajah J; Walraven JEW; Jaeger M; van Engen-van Grunsven ACH; Smit JW; Netea-Maier RT
    Eur Thyroid J; 2024 Aug; 13(4):. PubMed ID: 39047141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
    Liu J; Liu Y; Lin Y; Liang J
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients.
    Yildirim-Poyraz N; Yazgan A; Ozdemir E; Gozalan A; Keskin M; Ersoy R; Turkolmez S; Cakir B
    Ann Nucl Med; 2014 Aug; 28(7):623-31. PubMed ID: 24823701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
    Gao WL; Wie LL; Chao YG; Wie L; Song TL
    Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sinomenine Hydrochloride Promotes TSHR-Dependent Redifferentiation in Papillary Thyroid Cancer.
    Zhang J; Zhao A; Jia X; Li X; Liang Y; Liu Y; Xie X; Qu X; Wang Q; Zhang Y; Gao R; Yu Y; Yang A
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
    Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-iodide symporter and its related solute carriers in thyroid cancer.
    Gong Z; Wei M; Vlantis AC; Chan JYK; Van Hasselt CA; Li D; Zeng X; Xue L; Tong MCF; Chen GG
    J Endocrinol; 2024 Apr; 261(1):. PubMed ID: 38329368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.